CERS
Price
$2.31
Change
-$0.08 (-3.35%)
Updated
Oct 22 closing price
Capitalization
465.52M
11 days until earnings call
Intraday BUY SELL Signals
ICUI
Price
$168.53
Change
+$7.69 (+4.78%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
4.02B
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CERS vs ICUI

CERS vs ICUI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CERS vs. ICUI commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a StrongBuy and ICUI is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CERS with price predictions
Oct 21, 2026

CERS's RSI Indicator ascends from oversold territory

The RSI Indicator for CERS moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 22 of the 28 cases the stock moved higher. This puts the odds of a move higher at 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on CERS as a result. In 78 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.

The Moving Average Convergence Divergence (MACD) for CERS just turned positive on October 20, 2026. Looking at past instances where CERS's MACD turned positive, the stock continued to rise in 32 of 44 cases over the following month. The odds of a continued upward trend are 73%.

Following a +7.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where CERS advanced for three days, in 170 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CERS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

CERS broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CERS entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.648) is normal, around the industry mean (2.923). P/E Ratio (-77.000) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (2.219) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. CERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CERS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
a Summary for ICUI with price predictions
Oct 21, 2026

ICUI's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for ICUI turned positive on September 24, 2026. Looking at past instances where ICUI's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ICUI's RSI Oscillator exited the oversold zone, 23 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ICUI as a result. In 62 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.

Following a +4.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where ICUI advanced for three days, in 193 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

The Aroon Indicator entered an Uptrend today. In 156 of 206 cases where ICUI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 76%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 60 cases where ICUI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICUI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.

ICUI broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. ICUI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.869) is normal, around the industry mean (4.952). ICUI has a moderately high P/E Ratio (134.033) as compared to the industry average of (36.644). Projected Growth (PEG Ratio) (0.081) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.808) is also within normal values, averaging (56.876).

The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICUI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

FUNDAMENTALS RATINGS
CERS vs ICUI: Fundamental Ratings
CERS
ICUI
OUTLOOK RATING
1..100
3169
VALUATION
overvalued / fair valued / undervalued
1..100
8
Undervalued
87
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9489
PRICE GROWTH RATING
1..100
5740
P/E GROWTH RATING
1..100
1996
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (8) in the Medical Specialties industry is significantly better than the same rating for ICUI (87). This means that CERS’s stock grew significantly faster than ICUI’s over the last 12 months.

CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ICUI (100). This means that CERS’s stock grew similarly to ICUI’s over the last 12 months.

ICUI's SMR Rating (89) in the Medical Specialties industry is in the same range as CERS (94). This means that ICUI’s stock grew similarly to CERS’s over the last 12 months.

ICUI's Price Growth Rating (40) in the Medical Specialties industry is in the same range as CERS (57). This means that ICUI’s stock grew similarly to CERS’s over the last 12 months.

CERS's P/E Growth Rating (19) in the Medical Specialties industry is significantly better than the same rating for ICUI (96). This means that CERS’s stock grew significantly faster than ICUI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSICUI
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
72%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
67%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 11 days ago
68%
Declines
ODDS (%)
Bearish Trend 15 days ago
83%
Bearish Trend 2 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
76%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (CERS: $2.39 vs. ICUI: $160.84)
Brand notoriety: CERS and ICUI are both not notable
CERS represents the Medical/Nursing Services, while ICUI is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: CERS: 89% vs. ICUI: 93%
Market capitalization -- CERS: $465.52M vs. ICUI: $4.21B
CERS [@Medical/Nursing Services] is valued at $465.52M. ICUI’s [@Pharmaceuticals: Other] market capitalization is $4.21B. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $173.92B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $156.8B. The average market capitalization across the [@Medical/Nursing Services] industry is $5.76B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 2 FA rating(s) are green while ICUI’s FA Score has 0 green FA rating(s).

  • CERS’s FA Score: 2 green, 3 red.
  • ICUI’s FA Score: 0 green, 5 red.
According to our system of comparison, CERS is a better buy in the long-term than ICUI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 4 TA indicator(s) are bullish while ICUI’s TA Score has 5 bullish TA indicator(s).

  • CERS’s TA Score: 4 bullish, 4 bearish.
  • ICUI’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, ICUI is a better buy in the short-term than CERS.

Price Growth

CERS (@Medical/Nursing Services) experienced а +6.70% price change this week, while ICUI (@Pharmaceuticals: Other) price change was -1.14% for the same time period.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.74%. For the same industry, the average monthly price growth was -3.62%, and the average quarterly price growth was +9.09%.

Reported Earning Dates

CERS is expected to report earnings on Nov 02, 2026.

ICUI is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Medical/Nursing Services (-1.62% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

@Pharmaceuticals: Other (+0.74% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

View a ticker or compare two or three
CERS
Daily Signal:
Gain/Loss:
ICUI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ICUI and

Correlation & Price change

A.I.dvisor indicates that over the last year, ICUI has been loosely correlated with CLPT. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ICUI jumps, then CLPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICUI
1D Price
Change %
ICUI100%
-0.15%
CLPT - ICUI
57%
Loosely correlated
-2.12%
ALGN - ICUI
50%
Loosely correlated
+0.58%
A - ICUI
50%
Loosely correlated
+2.74%
MMSI - ICUI
50%
Loosely correlated
+0.24%
BLCO - ICUI
49%
Loosely correlated
+1.48%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PURR9.620.47
+5.14%
Hyperliquid Strategies Inc
CARL14.310.13
+0.92%
Carlsmed Inc
OCCIM24.83-0.05
-0.20%
OFS Credit Company Inc
EGO34.96-0.22
-0.63%
Eldorado Gold Corp
VERI0.57-0.02
-3.79%
Veritone